Task force 7. Evaluation and management of risk factors for the individual patient (case management)

Journal of the American College of Cardiology

Volumn 27, Issue 5, 1996, Pages 1030-1039

  Swan, H J C ^a   Gersh, Bernard J ^a   Graboys, Thomas B ^a   Ullyot, Daniel J ^a  

^a Department of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; HEPARIN; WARFARIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIET; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOSIS; CASE MANAGEMENT; PATIENT SELECTION; REVIEW;

CASE MANAGEMENT; CORONARY DISEASE; HUMANS; PATIENT SELECTION; RISK FACTORS;

EID: 0029887773     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)87735-7     Document Type: Conference Paper

References (37)

1. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
2. Hulley SB, Walsh JM, Newman TB. Health policy on blood cholesterol. Time to change directions. Circulation 1992;86(3):1026-9.
3. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301(6747):309-14.
4. Stamler J, Stamler R, Brown WV. Serum cholesterol. Doing the right thing. Circulation 1993;88(4 Pt 1): 1954-60.
5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
6. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306(6889):1367-73.
7. Silberberg JS, Henry DA. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention. 2. Implications for heart disease prevention in Australia. Med J Aust 1991;155(10):665-74.
8. Swan HJ. Why cardiologists must be interested in lipids. Am J Cardiol 1995;75(15):1067-8.
9. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326(5):310-8.
10. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
11. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
12. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
13. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-13.
14. Roberts WC. Getting cardiologists interested in lipids. Am J Cardiol 1993;72:744-5.
15. Stevenson JC, Godsland IF, Wynn V. Cardiologists rebuked. Lancet 1994; 344:1557
16. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272:1335-40.
17. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
18. Gotto AM Jr. Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 1995;92:646-56.
19. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-500.
20. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-9.
21. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
22. Sullivan JM, Frohlich ED, Lewis RP, Pasternak RC. Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 10: training in preventive cardiovascular medicine. J Am Coll Cardiol 1995;25:33-4.
23. Levy D, Wilson PW, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 1990;119:712-7.
24. Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2-4.
25. Pearson T, Rapaport E, Criqui M, et al. Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. Circulation 1994;90(6):3125-33.
26. Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation 1992;86:1664-9.
27. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993;328(17):1213-9.
28. Roberts WC. The ineffectiveness of a commonly recommended lipid-lowering diet in significantly lowering the serum total and low-density lipoprotein cholesterol levels. Am J Cardiol 1994;73(8):623-4.
29. Pearson TA, Terry P. What to advise patients about drinking alcohol. The clinician's conundrum. JAMA 1994;272:967-8.
30. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269(23):3015-23.
31. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
32. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
33. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-83.
34. Curfman GD. Is exercise beneficial - or hazardous - to your heart? N Engl J Med 1993;329:1730-1.
35. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86:1-11.
36. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336(8708): 129-33.
37. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.